X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (98) 98
female (92) 92
oncology (88) 88
breast cancer (71) 71
middle aged (71) 71
adult (70) 70
aged (66) 66
breast neoplasms - drug therapy (58) 58
index medicus (58) 58
breast neoplasms - pathology (50) 50
chemotherapy (46) 46
cancer (45) 45
metastasis (38) 38
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
treatment outcome (29) 29
care and treatment (28) 28
trastuzumab (25) 25
antineoplastic agents - therapeutic use (22) 22
survival (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
neoplasm metastasis (21) 21
aged, 80 and over (20) 20
clinical trials (20) 20
disease-free survival (20) 20
metastatic breast cancer (19) 19
breast neoplasms - metabolism (18) 18
therapy (18) 18
docetaxel (17) 17
medicine & public health (17) 17
breast neoplasms - genetics (16) 16
paclitaxel (16) 16
prognosis (16) 16
receptor, erbb-2 - metabolism (16) 16
tumors (16) 16
dose-response relationship, drug (15) 15
hematology, oncology and palliative medicine (15) 15
research (15) 15
analysis (14) 14
breast neoplasms - mortality (14) 14
cancer therapies (14) 14
capecitabine (14) 14
metastases (14) 14
neoplasm staging (14) 14
patients (14) 14
combination (13) 13
drug administration schedule (13) 13
male (13) 13
prospective studies (13) 13
antimitotic agents (12) 12
antineoplastic agents (12) 12
antineoplastic agents - adverse effects (12) 12
erbb-2 protein (12) 12
fluorouracil - administration & dosage (12) 12
life sciences (12) 12
paclitaxel - administration & dosage (12) 12
survival analysis (12) 12
toxicity (12) 12
deoxycytidine - analogs & derivatives (11) 11
efficacy (11) 11
neoplasms - drug therapy (11) 11
antibodies, monoclonal, humanized (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
bevacizumab (10) 10
carcinoma (10) 10
deoxycytidine - administration & dosage (10) 10
drug therapy (10) 10
retrospective studies (10) 10
safety (10) 10
solid tumors (10) 10
survival rate (10) 10
breast neoplasms - chemistry (9) 9
cancer patients (9) 9
cyclophosphamide (9) 9
maximum tolerated dose (9) 9
oncology, experimental (9) 9
pharmacokinetics (9) 9
receptor, erbb-2 - analysis (9) 9
trial (9) 9
anthracycline (8) 8
antibodies, monoclonal, humanized - therapeutic use (8) 8
antineoplastic agents - administration & dosage (8) 8
brain neoplasms - secondary (8) 8
breast (8) 8
breast carcinoma (8) 8
doxorubicin (8) 8
epidermal growth factor (8) 8
fluorouracil - analogs & derivatives (8) 8
follow-up studies (8) 8
kaplan-meier estimate (8) 8
medical prognosis (8) 8
medicine (8) 8
ovarian cancer (8) 8
product development (8) 8
quinazolines - administration & dosage (8) 8
administration, oral (7) 7
antibodies, monoclonal - administration & dosage (7) 7
antibodies, monoclonal - therapeutic use (7) 7
antibodies, monoclonal, humanized - adverse effects (7) 7
cyclophosphamide - administration & dosage (7) 7
cytotoxicity (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS Medicine, ISSN 1549-1277, 12/2016, Volume 13, Issue 12, pp. e1002201 - e1002201
Journal Article
The Breast, ISSN 0960-9776, 11/2017, Volume 36, pp. S27 - S27
Journal Article
The Breast, ISSN 0960-9776, 11/2017, Volume 36, p. S27
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 732 - 742
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer... 
Hematology, Oncology and Palliative Medicine | RECEPTOR | ONCOLOGY | PERTUZUMAB | DOCETAXEL | GUIDELINES | Capecitabine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Young Adult | Breast Neoplasms - chemistry | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Lapatinib | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Trastuzumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms, Male - chemistry | Disease-Free Survival | Retreatment | Taxoids - administration & dosage | Vomiting - chemically induced | Aspartate Aminotransferases - blood | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Breast Neoplasms, Male - pathology | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | Care and treatment | Breast cancer | Metastasis | Patient outcomes | Analysis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 19, pp. 1783 - 1791
Women with metastatic breast cancer that had progressed during treatment with trastuzumab plus a taxane were assigned to lapatinib plus capecitabine or to... 
CAPECITABINE | LAPATINIB | MEDICINE, GENERAL & INTERNAL | THERAPY | PHASE-II | ANTIBODY | RECEPTOR | PLUS | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Young Adult | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Maytansine - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Survival Rate | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Deoxycytidine - analogs & derivatives | Trastuzumab | Drugs | Dose-response relationship (Biochemistry) | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Comparative analysis | Thrombocytopenia | Chemotherapy | Epidermal growth factor | Vomiting | Diarrhea | Cytotoxicity | Nausea | Survival | ErbB-2 protein | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 2017, Volume 12, Issue 5, p. e0175998
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 64 - 71
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2108 - 2121
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 20, pp. 1925 - 1936
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2010, Volume 122, Issue 1, pp. 181 - 188
Long-term bisphosphonate therapy is associated with increased risk of osteonecrosis of the jaw (ONJ). In a retrospective analysis, a 16% ONJ incidence was... 
Angiogenesis | Bisphosphonate | Medicine & Public Health | Osteonecrosis of the jaw | Oncology | Metastatic breast cancer | Bevacizumab | MULTIPLE-MYELOMA | RISK-FACTORS | EFFICACY | BONE METASTASES | PREVENTION | ONJ | ONCOLOGY | PROSTATE-CANCER | EXPERIENCE | ENDOTHELIAL GROWTH-FACTOR | Prospective Studies | Osteonecrosis - epidemiology | Humans | Jaw Diseases - prevention & control | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Incidence | Jaw Diseases - chemically induced | Antibodies, Monoclonal, Humanized | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Vinblastine - analogs & derivatives | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Female | Paclitaxel - administration & dosage | Angiogenesis Inhibitors - adverse effects | Diphosphonates - adverse effects | Multicenter Studies as Topic - statistics & numerical data | Randomized Controlled Trials as Topic - statistics & numerical data | Double-Blind Method | Jaw Diseases - epidemiology | Breast Neoplasms - drug therapy | Oral Hygiene | Drug Synergism | Breast Neoplasms - complications | Taxoids - administration & dosage | Breast Neoplasms - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Genes, erbB-2 | Aged | Osteonecrosis - chemically induced | Osteonecrosis - prevention & control | Care and treatment | Analysis | Phosphonates | Clinical trials | Bones | Breast cancer | Angiogenesis inhibitors | Health aspects | Necrosis
Journal Article